Grace Therapeutics, Inc.

Grace Therapeutics, Inc. company information, Employees & Contact Information

Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases. The Company’s novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery – all which could help to increase treatment compliance and improve patient outcomes. The Company is focused on well-understood diseases that are poorly served by available therapies or have no approved therapies. Acasti is initially targeting three underserved orphan diseases - Subarachnoid Hemorrhage (SAH), Ataxia Telangiectasia (A-T), and Postherpetic Neuralgia (PHN) – all with sizable patient populations and significant market opportunity. The Company’s three lead clinical assets have all been granted Orphan Drug Designation by the FDA providing seven years of marketing exclusivity post-launch in the United States and are protected by over 40 granted and pending patents.

Company Details

Employees
19
Address
3009, Boul. De La Concorde E., Suite 102,canada
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Laval.
HQ
Laval, Québec
Looking for a particular Grace Therapeutics, Inc. employee's phone or email?

Grace Therapeutics, Inc. Questions

News

Acasti Pharma changes name to Grace Therapeutics - MSN

Acasti Pharma changes name to Grace Therapeutics MSN

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire

Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. GlobeNewswire

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures - Stock Titan

Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures Stock Titan

Reed Smith represents Grace Therapeutics in signing of a merger agreement with Acasti Pharma - Reed Smith LLP

Reed Smith represents Grace Therapeutics in signing of a merger agreement with Acasti Pharma Reed Smith LLP

Acasti submits aSAH Phase III safety study protocol to FDA - Clinical Trials Arena

Acasti submits aSAH Phase III safety study protocol to FDA Clinical Trials Arena

Weeks after laying off 'substantially all' employees, Acasti Pharma insists its approval plans remain on track - Fierce Biotech

Weeks after laying off 'substantially all' employees, Acasti Pharma insists its approval plans remain on track Fierce Biotech

Acasti, seeking to expand use of old steroid, posts clinical data on oral spray in rare disease - Fierce Pharma

Acasti, seeking to expand use of old steroid, posts clinical data on oral spray in rare disease Fierce Pharma

Out of the sea and into the factory for Acasti’s heart drug ingredient - Chemical & Engineering News

Out of the sea and into the factory for Acasti’s heart drug ingredient Chemical & Engineering News

Acasti: Fiscal Q3 Earnings Snapshot - qz.com

Acasti: Fiscal Q3 Earnings Snapshot qz.com

US-based Acasti Pharma to buy Indian origin pharma firm Grace - The Economic Times

US-based Acasti Pharma to buy Indian origin pharma firm Grace The Economic Times

Acasti appoints WuXi to conduct STRIVE-ON trial - Clinical Trials Arena

Acasti appoints WuXi to conduct STRIVE-ON trial Clinical Trials Arena

Acasti Pharma (ACST) Stock Price, News & Analysis - MarketBeat

Acasti Pharma (ACST) Stock Price, News & Analysis MarketBeat

Neptune Technologies & Bioressources Inc. Enters Pharmaceutical Market With Onemia(TM) Launch by Acasti Pharma Inc. - NBC News

Neptune Technologies & Bioressources Inc. Enters Pharmaceutical Market With Onemia(TM) Launch by Acasti Pharma Inc. NBC News

Acasti abandons omega-3 filing after 2nd phase 3 flop - Fierce Biotech

Acasti abandons omega-3 filing after 2nd phase 3 flop Fierce Biotech

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 - GlobeNewswire

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 GlobeNewswire

Acasti Pharma Reports Third Quarter 2023 Operational Results - Stock Titan

Acasti Pharma Reports Third Quarter 2023 Operational Results Stock Titan

%%title%% %%page%% %%sep%% - Cantech Letter

%%title%% %%page%% %%sep%% Cantech Letter

Acasti Pharma reports positive interim data from SAH therapy trial - Clinical Trials Arena

Acasti Pharma reports positive interim data from SAH therapy trial Clinical Trials Arena

Top Grace Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant